Results 241 to 250 of about 2,936,501 (309)

Multimodal analysis of cell-free DNA to improve early detection of gastric cancer. [PDF]

BMC Cancer
Long VD, Huynh LAK, Vo DH, Nguyen THH, Van TTV, Nguyen GTH, Doan TN, Nguyen VH, Tran QD, Dang QT, Nguyen VTA, Ho LMQ, Ha TPD, Dang TND, Nguyen PTN, Nguyen KT, Ho VC, Le TL, Nguyen THN, Tu NH, Tran TS, Jasmine TX, Vo TL, Nai THT, Tran TT, Truong MH, Tran NC, Nguyen TC, Nguyen TT, Le BT, Tang VP, Nguyen TT, Nguyen AT, Vu HG, Van Phan T, Nguyen TNT, Cao HA, Nguyen TH, Tu LN, Giang H, Phan MD, Nguyen HN, Nguyen VTC, Tran LS.   +43 more
europepmc   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source

Machine learning-driving optimization and spatial assembly of a cell-free system for high-yield liquiritigenin production. [PDF]

Adv Biotechnol (Singap)
Liu F, Zhao SB, Liu YH, Li JF, Lin NQ, Mutailifu M, Xu P, Liu JZ.   +7 more
europepmc   +1 more source

Molecular cancer prevention: Intercepting disease

Molecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco, Tej Pandya, Charles Swanton   +2 more
wiley   +1 more source

Immunoregulatory properties of cell free DNA. [PDF]

Cell Mol Life Sci
Ferrera F, Altosole T, Tardito S, Astone G, Bernardi C, Parodi A, Marini C, Conteduca G, Cichero E, Salis A, Arpesella L, Camporesi L, Lagazio A, Rigo V, Pigozzo A, Damonte G, Fossa P, Fenoglio D, De Palma R, Inghirami G, Filaci G.   +20 more
europepmc   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Accurate and reliable detection of clonal hematopoiesis in plasma cell-free DNA. [PDF]

Blood Adv
Parker AC, Van Amburg JC, Pershad Y, Ong DA, Hoey KJ, Farady CJ, Rauch PJ, Mendelson MM, Heimlich JB, Ferrell PB, Bick AG.   +10 more
europepmc   +1 more source

Circulating tumor cell viability during and after radiotherapy mirrors treatment response in cancer patients

Molecular Oncology, EarlyView.
Radiotherapy (RT) response depends on the DNA repair capacity of tumor and host cells. We show that circulating tumor cell (CTC) counts and apoptosis rates before and after RT predict treatment response and outcome, which can be accessed via easily accessible liquid biopsy approaches. Created in BioRender. Wikman, H.
Yvonne Goy, Jana Löptien, Cornelia Coith, Afroditi Nanou, Katharina Hintelmann, Pinnschmidt Hans, Cordula Petersen, Klaus Pantel, Sabine Riethdorf, Kerstin Borgmann, Harriet Wikman   +10 more
wiley   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell-free DNA. [PDF]

Mol Oncol
Maansson CT, Nielsen AL, Sorensen BS.
europepmc   +1 more source

Targeting TNBC: core–shell polycationic polyurea dendrimers with inherent anticancer activity

FEBS Open Bio, EarlyView.
Core–shell polycationic PURE dendrimers were tested in TNBC‐derived tumor models. Both formulations selectively targeted TNBC and effectively reduced tumor volume. PUREG4‐OEI48 suppressed tumor growth without detectable toxicity, whereas PUREG4‐OCEI24, despite showing efficacy, induced hepatic toxicity.
Adriana Cruz, Bruna Abreu, Cindy Mendes, Catarina Freitas‐Dias, Filipe Gonçalves, Fernanda Silva, José Ramalho, Saudade André, Vasco D. B. Bonifácio, Jacinta Serpa   +9 more
wiley   +1 more source